Caroline is a partner at EcoR1 Capital, where she focuses on investing in private and public biotechnology companies and has led multiple investments in the cell and gene therapy space. She also serves as chief investment officer of Panacea Acquisition Corporation. Prior to EcoR1, Caroline was a healthcare investment banker at Credit Suisse. She is a board member of Neurogene Inc. and Notch Therapeutics, and previously served as a board member of Prevail Therapeutics and Accent Therapeutics. She received a B.A. in economics from Georgetown University.